Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24211029 | 0.85 | ADRA2A (0.44) | DGAT1NPC1ADRA2AF2RL1 | |
| SCHEMBL31357963 | 0.84 | DGAT1 (0.33) | DGAT1ADRA2AF2RL1 | |
| SCHEMBL30304731 | 0.84 | DGAT1 (0.35) | DGAT1NPC1ADRA2AF2RL1 | |
| SCHEMBL29340464 | 0.84 | DGAT1 (0.37) | DGAT1ADRA2AF2RL1 | |
| SCHEMBL31009894 | 0.84 | DGAT1 (0.37) | DGAT1ADRA2AF2RL1 | |
| SCHEMBL20129641 | 0.82 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL22732003 | 0.82 | F2RL1 (0.33) | DGAT1NPC1RAB9AADRA2AF2RL1 | |
| SCHEMBL31433542 | 0.82 | DGAT1 (0.39) | DGAT1F2RL1 | |
| SCHEMBL25319549 | 0.81 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL24344356 | 0.81 | DGAT1 (0.36) | DGAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4562014-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| EP-4433477-A1 | PAD4 INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118679162-A | PAD4 inhibitors and uses thereof | 锐格药业公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4373814-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| EP-3475275-B1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | DGAT1 1155/4885NPC1 226/4885RAB9A 2561/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | DGAT1 4426/4885NPC1 4705/4885RAB9A 3181/4885 |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK1 | DGAT1 2712/4885NPC1 2601/4885RAB9A 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.